Plain language summary An analysis from the OnCovid registry on the impact of chemotherapy and SARS-CoV-2 vaccines on clinical outcomes of patients with soft tissue sarcoma and COVID-19 Soft tissue sarcomas (STS) are a group of rare and aggressive tumours, usually treated with high dose cytotoxic chemotherapy. To date no clear evidence exists on the impact of COVID-19 in patients with STS, nor on the potential impact of recent chemotherapy and prior SARS-CoV-2 vaccination in this specific patient population. This is the 1st study to show COVID-19 outcomes in patients with STS, highlighting a substantial vaccine efficacy with no negative impact of recent chemotherapy on COVID-19 outcomes.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, pandemic, Vaccines, Chemotherapy, Sarcoma, soft tissue sarcoma,
【저자키워드】 COVID-19, SARS-CoV-2, pandemic, Vaccines, Chemotherapy, Sarcoma, soft tissue sarcoma,